P-selectin: A common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 8, 2007, Pages 1103-1117

  Ludwig, Ralf J ^a   Schön, Michael P ^b,c   Boehncke, Wolf Henning ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cardiovascular disease; Inflammation; Metastasis; P selectin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BIMOSIAMOSE; CD11B ANTIGEN; CELL ADHESION MOLECULE; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR; HEPARIN; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; METHACHOLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NADROPARIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLACEBO; SODIUM CHLORIDE; THROMBOPLASTIN; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC RHINITIS; ASTHMA; BLEEDING TIME; BLOOD CLOTTING; BRONCHOSPASM; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL STIMULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; GRAFT SURVIVAL; HEART INFARCTION; HEMOSTASIS; HOST RESISTANCE; HUMAN; INFLAMMATION; INHIBITION KINETICS; KIDNEY TRANSPLANTATION; LEUKOCYTE MIGRATION; LICHEN PLANUS; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; PATCH TEST; PRICK TEST; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SECRETION; PSORIASIS; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION MEDIATORS; NEOPLASM METASTASIS; P-SELECTIN;

EID: 34547813033     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.8.1103     Document Type: Review

References (130)

1. KHORANA AA, FINE RL: Pancreatic cancer and thromboembolic disease. Lancet Oncol. (2004) 5:655-663.
2. LEE AY: Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat. Rev. (2002) 28:137-140.
3. WINTER PC: The pathogenesis of venous thromboembolism in cancer. emerging links with tumour biology. Hematol. Oncol. (2006) 24:126-133.
4. SCHÖN M, BOEHNCKE WH: Psoriasis - immunopathogenesis, genetics and therapeutic perspectives. N. Engl. J. Med. (2005) 352:1899-1912.
5. O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2591-2602.
6. MALLBRIS L, AKRE O, GRANATH F et al.: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol. (2004) 19:225-230.
7. GELFAND JM, NEIMANN AL, SHIN DB et al.: Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 296:1735-1741.
8. LUDWIG RJ, HERZOG C, ROSTOCK A et al.: Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. (2007) 156:271-276.
9. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular death in rheumatoid arthritis. Arthitis Rheum. (2005) 52:722-732.
10. MATSUDA H, USHIO H, GEBA GP, ASKENASE PW: Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies. J. Immunol. (1997) 158:2891-2897.
11. GEBA GP, PTAK W, ANDERSON GM et al.: Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J. Immunol. (1996) 157:557-565.
12. GASIC GJ, GASIC TB, STEWART CC: Antimetastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. USA (1968) 61:46-52.
13. DIACOVO TG, CATALINA MD, SIEGELMAN MH, VON ANDRIAN UH: Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin deficient mice. J. Exp. Med. (1998) 187:197-204.
14. DYMICKA-PIEKARSKA V, MATOWICKA-KARNA J, GRYKO M, KEMONA-CHETNIK I, KEMONA H: Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb. Res. (2006) [Epub ahead of print].
15. LUDWIG RJ, SCHULTZ JE, BOEHNCKE WH et al.: Activated, but not resting platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J. Invest. Dermatol. (2004) 122:830-836.
16. GEAR AR, CAMERINI D: Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation (2003) 10:335-350.
17. VON HUNDELSHAUSEN P, WEBER C: Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. (2007) 100:27-40.
18. MCEVER RP: Regulation of function and expression of P-selectin. Agents Actions Suppl. (1995) 47:117-119.
19. BEVILACQUA MP, NELSON RM: Selectins. J. Clin. Invest. (1993) :379-387.
20. EPPIHIMER MJ, RUSSELL J, ANDERSON DC et al.: Modulation of P-selectin expression in the postischemic intestinal microvasculature. Am. J. Physiol. (1997) 273:G1326-G1332.
21. ARMSTEAD VE, MINCHENKO AG, CAMPBELL B, LEFER AM: P-selectin is up-regulated in vital organs during murine traumatic shock. FASEB J. (1997) 11:1271-1279.
22. MAYADAS TN, JOHNSON RC, RAYBURN H, HYNES RO, WAGNER DD: Leukocyte rolling and extravasation are severely compromised in P-selectin-deficient mice. Cell (1993) 74:541-554.
23. FRENETTE PS, MOYNA C, HARTWELL DW et al.: Platelet-endothelial interactions in inflamed mesenteric venules. Blood (1998) 91:1318-1324.
24. TANG T, FRENETTE PS, HYNES RO, WAGNER DD, MAYADAS TN: Cytokine-induced meningitis is dramatically attenuated in mice deficient in endothelial selectins. J. Clin. Invest. (1996) 97:2485-2490.
25. SUBRAMANIAM M, SAFFARIPOUR S, WATSON SR et al.: Reduced recruitment of inflammatory cells in a contact hypersensitivity response in P-selectin-deficient mice. J. Exp. Med. (1995) 181:2277-2282.
26. SUBRAMANIAM M, FRENETTE PS, SAFFARIPOUR S et al.: Defects in hemostasis in P-selectin-deficient mice. Blood (1996) 87:1238-1242.
27. BORSIG L, WONG R, HYNES RO, VARKI NM, VARKI A: Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. USA (2002) 99:2193-2198.
28. LUDWIG RJ, BOEHME B, PODDA M et al.: Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. (2004) 64:2743-2750.
29. LUDWIG RJ, BOEHNCKE WH: Psoriasis and risk of myocardial infarction. JAMA (2007) 297:362-363.
30. SCHON M, LUDWIG RJ: Leukocyte trafficking to inflamed skin - molecular mechanisms and implications for therapeutic target molecules. Expert Opin. Ther. Targets (2005) 9:225-243.
31. BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60-66.
32. VON ANDRIAN UH, MACKAY CR: T-cell function and migration. Two sides of the same coin. N. EngL J. Med. (2000) 343:1020-1034.
33. RADEKE HH, LUDWIG RJ, BOEHNCKE WH: Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Exp. Dermatol. (2005) 14:641-666.
34. WENINGER W, ULFMAN LH, CHENG G et al.: Specialized contributions by alpha(1,3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal microvessels. Immunity (2000) 12:665-676.
35. YANG J, FURIE BC, FURIE B: The biology of P-selectin glycoprotein ligand-l: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb. Haemost. (1999) 81:1-7.
36. MUNOZ FM, HAWKINS EP, BULLARD DC, BEAUDET AL, KAPLAN SL: Host defense against systemic infection with Streptococcus pneumoniae is impaired in E-, P-, and E-/P-selectin-deficient mice. J. Clin. Invest. (1997) 100:2099-2106.
37. ZARBOCK A, SINGBARTL K, LEY K: Complete reversal of add-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest. (2006) 116:3211-3219.
38. KOWAL K, PAMPUCH A, KOWAL-BIELECKA O, DUBUSKE LM, BODZENTA-LUKASZYK A: Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin. Exp. Allergy (2006) 36:426-432.
39. LALLY F, SMITH E, FILER A et al.: A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. (2005) 52:3460-3469.
40. RUTH JH, AMIN MA, WOODS JM et al.: Accelerated development of arthritis in mice lacking endothelial selectins. Arthritis Res. Ther. (2005) 7:R959-R970.
41. LITTLER AJ, BUCKLEY CD, WORDSWORTH P et al.: A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. (1997) 36:164-169.
42. LUKACS NW, JOHN A, BERLIN A et al.: E- and P-selectins are essential for the development of cockroach allergen-induced airway responses. J. Immunol. (2002) 169:2120-2125.
43. MAYADAS TN, MENDRICK DL, BRADY HR et al.: Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. (1996) 49:1342-1349.
44. FURMAN MI, BENOIT SE, BARNARD MR et al.: Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J. Am. Coll. Cardiol. (1998) 31:352-358.
45. COLLINS CE, CAHILL MR, NEWLAND AC, RAMPTON DS: platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology (1994) 106:840-845.
46. JOSEPH JE, HARRISON P, MACKIE IJ, ISENBERG DA, MACHIN SJ: Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br. J. Haematol. (2001) 115:451-459.
47. WOOLLARD KJ, KLING D, KULKARNI S et al.: Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ. Res. (2006) 98:149-156.
48. VEALE DJ, MAPLE C, KIRK G, MCLAREN M, BELCH JJ: Soluble cell adhesion molecules - P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand. J. Rheumatol. (1998) 27:296-299.
49. DIACOVO TG, PURI KD, WARNOCK RA, SPRINGER TA, VON ANDRIAN UH: Platelet mediated lymphocyte delivery to high endothelial venules. Science (1996) 273:252-273.
50. MARTINS PC, ZWAGINGA JJ: Leukocyte-platelet aggregates: new particles reflecting and effecting cardiovascular disease. Thromb. Haemost. (2005) 94:1120-1121.
51. LI N, JI Q, HJEMDAHL P: platelet-lymphocyte conjugation differs between lymphocyte subpopulations. J. Thromb. Haemost. (2006) 4:874-881.
52. BLANKS JE, MOLL T, EYTNER R, VESTWEBER D: Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates β 2-integrin mediated cell attachment to ICAM-1. Eur. J. Immunol (1998) 28:433-443.
53. HIDARI KI, WEYRICH AS, ZIMMERMAN GA, MCEVER RP: Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. J. Biol. Chem. (1997) 272:28750-28756.
54. WEYRICH AS, MCINTYRE TM, MCEVER RP, PRESCOTT SM, ZIMMERMAN GA: Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and TNF-α secretion. Signal integration and NF-κB translocation. J. Clin. Invest. (1995) 95:2297-2303.
55. PITCHFORD SC, MOMI S, GIANNINI S et al.: Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood (2005) 105:2074-2081.
56. MAY AE, KALSCH T, MASSBERG S et al.: Engagement of glycoprotein IIb/IIIa (α(IIb)β3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation (2002) 106:2111-2117.
57. HUO Y, SCHOBER A, FORLOW SB et al.: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. (2003) 9:61-67.
58. SCHOBER A, MANKA D, VON HUNDELSHAUSEN P et al.: Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation (2002) 106:1523-1529.
59. VON HUNDELSHAUSEN P, WEBER KS, HUO Y et al.: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 103:1772-1777.
60. STENBERG PE, MCEVER RP, SHUMAN MA, JACQUES YV, BAINTON DF: A platelet α-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J. Cell Biol (1985) 101:880-886.
61. SULLIVAN VV, HAWLEY AE, FARRIS DM et al.: Decrease in fibrin content of venous thrombi in selectin-deficient mice. J. Surg. Res. (2003) 109:1-7.
62. CAMBIEN B, WAGNER DD: A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol. Med. (2004) 10:179-186.
63. OOSTINGH GJ, POZGAJOVA M, LUDWIG RJ et al.: Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. Haematologica (2007) 92:502-512.
64. MASSBERG S, KONRAD I, SCHURZINGER K et al.: Platelets secrete stromal cell-derived factor lα and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J. Exp. Med. (2006) 203:1221-1233.
65. ANDRE P, HARTWELL D, HRACHOVINOVA I, SAFFARIPOUR S, WAGNER DD: Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. USA (2000) 97:13835-13840.
66. HRACHOVINOVA I, CAMBIEN B, HAFEZI-MOGHADAM A et al.: Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. (2003) 9:1020-1025.
67. GIESEN PL, RAUCH U, BOHRMANN B et al.: Blood-borne tissue factor, another view of thrombosis. Proc. Natl. Acad. Sci. USA (1999) 96:2311-2315.
68. RAUCH U, NEMERSON Y: Tissue factor, the blood, and the arterial wall. Trends Cardiovasc. Med. (2000) 10:139-143.
69. FALATI S, LIU Q, GROSS P et al.: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. (2003) 197:1585-1598.
70. KAGESHITA T, HIRAI S, KIMURA T et al.: Association between sialyl Lewis(a) expression and tumor progression in melanoma. Cancer Res. (1995) 55:1748-1751.
71. MAKINO T, SHIMADA Y, MAEDA M, KOMOTO I, IMAMURA M: Carbohydrate antigens as a risk factor for hematogenous recurrence of esophageal squamous cell carcinoma patients. Oncol. Rep. (2001) 8:981-985.
72. BAFALOUKOS D, GOGAS H, GEORGOULIAS V et al.: Temozolomide in combination with docetaxel in patients with advanced melanoma: a Phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol. (2002) 20:420-425.
73. OGAWA J, INOUE H, KOIDE S: Expression of a-1,3-fucosyltransferase type IV and VII is related to poor prognosis in lung cancer. Cancer Res. (1996) 56:325-329.
74. KIM YJ, BORSIG L, VARKI NM, VARKI A: P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. USA (1998) 95:9325-9330.
75. NIESWANDT B, HAFNER M, ECHTENACHER B, MANNEL DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. (1999) 59:1295-1300.
76. VARKI NM, VARKI A: Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. (2002) 28:53-66.
77. BROWDER T, FOLKMAN J, PIRIE-SHEPHERD S: The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. (2000) 275(3):1521-1524.
78. CAMERON MD, SCHMIDT EE, KERKVLIET N et al.: Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. (2000) 60:2541-2546.
79. LUZZI KJ, MACDONALD IC, SCHMIDT EE et al.: Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. (1998) 153:865-873.
80. CHAMBERS AF, GROOM AC, MACDONALD IC: Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer (2002) 2:563-572.
81. VESTWEBER D, BLANKS JE: Mechanisms that regulate the function of the selectins and their ligands [published erratum appears in Physiol Rev 2000 Jul;80(3):following table of contents]. Physiol. Rev. (1999) 79:181-213.
82. WEYRICH AS, MCINTYRE TM, MCEVER RP, PRESCOTT SM, ZIMMERMAN GA: Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and TNF-α secretion. Signal integration and NF-κB translocation. J. Clin. Invest. (1995) 95:2297-2303.
83. CARRIERE V, COLISSON R, JIGUET-JIGLAIRE C et al.: Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res. (2005) 65:11639-11648.
84. LAUBLI H, STEVENSON JL, VARKI A, VARKI NM, BORSIG L: L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res. (2006) 66:1536-1542.
85. LUDWIG RJ, ALBAN S, BISLIAN R et al.: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb. Haemost. (2006) 95:535-540.
86. STEVENSON JL, CHOI SH, VARKI A: Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. (2005) 11:7003-7011.
87. BORSIG L: Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol. Sci. (2004) 19:16-21.
88. ZACHARSKI LR, ORNSTEIN DL: Heparin and cancer. Thromb. Haemost. (1998) 80:10-23.
89. VARKI NM, VARKI A: Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. (2002) 28(1):53-66.
90. KAKKAR AK, LEVINE MN, KADZIOLA Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer, the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. (2004) 10:1944-1948.
91. ALTINBAS M, COSKUN HS, ER O et al.: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. (2004) 2:1266-1271.
92. LUDWIG RJ, ALBAN S, BOEHNCKE WH: Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini-Rev. Med. Chem. (2006) 6:1009-1023.
93. SCHON M, OOSTINGH GJ, WIENRICH BG, LUDWIG RJ, SCHÖN MP: Selectin-dependent interactions of melanoma cells with endothlial cells and their anibody- or small-molecule-mediated modulation. Exp. Dermatol. (2007) 16:252-252.
94. PALMA-VARGAS JM, TOLEDO-PEREYRA L, DEAN RE et al.: Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J. Am. Coll. Surg. (1997) 185:365-372.
95. BEEH KM, BEIER J, MEYER M et al.: Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm. Pharmacol. Ther. (2006) 19:233-241.
96. FRIEDRICH M, BOCK D, PHILIPP S et al.: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. (2006) 297:345-351.
97. ANG YS, MAHMUD N, WHITE B et al.: Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment. Pharmacol. Ther. (2000) 14:1015-1022.
98. BLOOM S, KIILERICH S, LASSEN MR et al.: Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment. Pharmacol. Ther. (2004) 19:871-878.
99. INGBER A, TRATTNER A, COHEN IR, MEKORI YA: Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity. Acta Derm. Venereol. (1994) 74:454-456.
100. BOWLER SD, SMITH SM, LAVERCOMBE PS: Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis. (1993) 147:160-163.
101. HODAK E, YOSIPOVITCH G, DAVID M et al.: Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J. Am. Acad. Dermatol. (1998) 38:564-568.
102. ALBAN S: From heparins to factor Xa inhibitors and beyond. Eur. J. Clin. Invest. (2005) 35:12-20.
103. KUMAR A, VILLANI MP, PATEL UK, KEITH JC Jr, SCHAUB RG: Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation (1999) 99:1363-1369.
104. MERTENS P, MAES A, NUYTS J et al.: Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. Am. Heart J. (2006) 152:125-128.
105. ORNSTEIN DL, ZACHARSKI LR: Cancer, thrombosis, and anticoagulants. Curr. Opin. Pulm. Med. (2000) 6:301-308.
106. LEBEAU B, CHASTANG C, BRECHOT JM et al.: Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer (1994) 74:38-45.
107. KLERK CPW, SMORENBURG SM, OTTEN HM et al.: The Effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. (2005) 23:2130-2135.
108. LEE AY, RICKLES FR, JULIAN JF et al.: Randomized comparison of low molecular weight heparin and coumarin derivates on the survival of patients with cancer and venom thromboembolism. J. Clin. Oncol. (2005) 23:2123-2129.
109. BORSIG L, WANG L, CAVALCANTE MC et al.: Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber: effect ON tumor metastasis and neutrophil recruitment. J. Biol. Chem. (2007) 282:14984-14991.
110. FRITZSCHE J, ALBAN S, LUDWIG RJ et al.: The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochem. Pharmacol. (2006).
111. SANTOSO S, SACHS UJ, KROLL H et al.: The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-l. J. Exp. Med. (2002) 196:679-691.
112. LUDWIG RJ, ZOLLNER TM, SANTOSO S et al.: Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J. Invest. Dermatol. (2005) 125:969-976.
113. AURRAND-LIONS M, LAMAGNA C, DANGERFIELD JP et al.: Junctional adhesion molecule-C regulates the early influx of leukocytes into tissues during inflammation. J. Immunol. (2005) 174:6406-6415.
114. SANTOSO S, ORLOVA VV, SONG K et al.: The homophilic binding of junctional adhesion molecule-C mediates tumor cell-endothelial cell interactions. J. Biol. Chem. (2005) 280:36326-36333.
115. LAMAGNA C, HODIVALA-DILKE KM, IMHOF BA, AURRAND-LIONS M: Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res. (2005) 65:5703-5710.
116. AYDT E, WOLFF G: Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Pathobiology (2002) 70:297-301.
117. KALPAKLIOGLU AF, DEMIREL YS, SARYAL S, MISIRLIGIL Z: Effect of pretreatment with heparin on pulmonary and cutaneous response. J. Asthma (1997) 34:337-343.
118. AHMED T, GARRIGO J, DANTA I: Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. (1993) 329:90-95.
119. CEYHAN B, CELIKEL T: Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest (1995) 107:1009-1012.
120. VANCHERI C, MASTRUZZO C, ARMATO F et al.: Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108:703-708.
121. DE CICCO M: The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rev. Oncol. Hematol. (2004) 50:187-196.
122. VILLMOW T, KEMKES-MATTHES B, MATZDORFF AC: Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb. Res. (2002) 108:139-145.
123. MATHUR A, ROBINSON MS, COTTON J, MARTIN JF, ERUSALIMSKY JD: Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb. Haemost. (2001) 85:989-994.
124. DE MARZO AM, PLATZ EA, SUTCLIFFE S et al.: Inflammation in prostate carcinogenesis. Nat. Rev. Cancer (2007) 7:256-269.
125. DEDRICK RL, BODARY S, GAROVOY MR: Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin. Biol. Ther. (2003) 3:85-95.
126. HONN KV, TANG DG, CHEN YQ: Platelets and cancer metastasis: more than an epiphenomenon. Semin. Thromb. Hemost. (1992) 18:392-415.
127. WEYRICH AS, MCINTYRE TM, MCEVER RP, PRESCOTT SM, ZIMMERMAN GA: Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and TNF-α secretion. Signal integration and NF-κB translocation. J. Clin. Invest. (1995) 95:2297-2303.
128. MCGREGOR L, MARTIN J, MCGREGOR JL: Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front. Biosci. (2006) 11:830-837.
129. HAVERKATE F, THOMPSON SG, PYKE SD, GALLIMORE JR, PEPYS MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet (1997) 349:462-466.
130. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation (1998) 97:425-428.